πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 40 of 173

  1. US 11015023

    Fire retardant compositions utilizing elemental sulfur

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11014980

    Transforming growth factor-beta-responsive polypeptides and their methods for use

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11014950

    Nucleotide analogs

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11016009

    Method for isolating extracellular vesicles using aqueous two-phase system

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11016093

    Disease-associated antigens and methods of use thereof

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11013704

    Compounds supports hematopoietic stem cells and red blood cells

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11013754

    Compositions and methods for treating cancer

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11013707

    Administration of oral methyldopa

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11014955

    Cyclic peroxides as prodrugs for selective delivery of agents

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11013818

    Library of pH responsive polymers and nanoprobes thereof

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11013787

    Sustained release formulation of interleukin-10 for wound treatment and related methods

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11013808

    Clinical formulations

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11013705

    Methods and compositions for supporting renal health

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11014921

    Therapeutic compounds and methods of use thereof

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11013740

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11013798

    Orf virus-based platform for vaccine delivery

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11008589

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11008590

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11008382

    Antibodies to oxidized phospholipids

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11007248

    Suppression of allergic lung inflammation and hyperreactivity

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11007385

    Use of cellular extracts for skin rejuvenation

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11007163

    Glutarate compounds for treating ischemia-reperfusion injuries

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11008334

    Compositions and methods for treating cancer

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11007147

    Hydrogel toxin-absorbing or binding nanoparticles

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11008553

    Halogenation of complex organic compounds

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11008381

    Antibodies to oxidized phospholipids

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11008372

    Targeting proteins for degradation

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11007281

    Nano/micromotors for active and dynamic intracellular payload delivery

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11000576

    Enzymes and methods for cleaving n-glycans from glycoproteins

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11000593

    Cellular or viral membrane coated nanostructures and uses thereof

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11000570

    Isoform Nell-1 peptide

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11000562

    Use of isolated fractions of mastic gum for treating optic neuropathy

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11001783

    Synthesis and use of Ο‰-hydroxylated polyunsaturated fatty acids

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11001863

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11001609

    Cell permeable cyclic peptide scaffolds

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11001892

    Methods of diagnosing endometriosis

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11000602

    Delivery of small interfering RNA and micro RNA through nanogels containing hydrophobic pseudo-peptides

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11000568

    Means and methods for treating copper-related diseases

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11001594

    Heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10993930

    Methods and materials for using Ruminococcus gnavus or Clostridium sporogenes to treat gastrointestinal disorders

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10993834

    Lacrimal system drug delivery device

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10993983

    Cyclic peptide epitopes and small-molecule mimics for inducing autophagy

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10994031

    Composites and compositions for therapeutic use and methods of making and using the same

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10995317

    NK cells exhibiting an adaptive phenotype and methods for preparing and for using

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10995156

    Acid-degradable and bioerodible modified polyhydroxylated materials

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10993959

    Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10993936

    Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10993419

    Genetically modified cells, tissues, and organs for treating disease

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.